1. Recognize the patterns of clinical presentation for muscle and nerve disease and determine the most appropriate laboratory tests and treatments based on the clinical pattern.
2. Identify the clinical phenotypes of peripheral neuropathies, myopathies, anterior horn cell disorders and neuromuscular junction diseases and how these phenotypes can dictate the appropriate laboratory evaluation as to the etiology of these neuromuscular disorders.
3. Case-based review the electrodiagnosis of common and uncommon entrapment neuropathies and radiculopathies, while discussing their management and reviewing criteria for demyelination supportive of CIDP in the proper clinical pattern.
4. Recognize the diverse presentations of immune neuropathy and distinguish them from a number of untreatable neuropathies. Discuss the concept of diagnostic certainty in immune neuropathies and current treatment strategies for classic CIDP, Lewis Sumner syndrome, multifocal motor neuropathy and distal acquired demyelinating neuropathy.
5. Discuss the symptoms of neuropathic pain, management guidelines and its practical management with discussion of recent CDC 2016 guidance on narcotics in chronic pain. Discuss clinical trials in cryptogenic sensory neuropathy (CSPN) and in diabetic painful neuropathy (DPN).
6. Review the different clinical presentations of motor neuron disease. Discuss recent updates in clinical practice including recent quality measures. Understand results of recent clinical trials and direction of ongoing studies including symptomatic therapies (for muscle strengthening, pseudobulbar affect, sialorrhea), disease modifiers that slow progression and stem cell research. Discuss the latest therapies in spinal muscular atrophy of antisense oligonucleotide therapy and in ALS of blocking oxidative stress.
7. Summarize the evaluation and treatment of acquired muscle disorders and review advances in autoantibodies particularly MDA-5, TIF1gamma, statin-associated autoimmune necrotizing myopathy (SANAM) and inclusion body myositis (IBM) and discuss ongoing research advances in the myositidis. Also review the approach to the evaluation and treatment of inherited muscle disorders including enzyme replacement therapy in Pompe and most recently in 2016 morpholino antisense oligomer exon skipping approval in Duchenne muscular dystrophy and the roles of other novel therapies such as deflazacort and dichlorphenamide.
8. Discuss the use of tailored immunosuppressive drugs and immunomodulation for the treatment of autoimmune neuromuscular disorders and other ongoing clinical research such as rituximab and gammaglobulins, intravenously and subcutaneously as well as significant recent progress in targeted monoclonal antibodies.
9. Identify new tests for diagnosing MG in patients who are acetylcholine receptor antibody negative. Learn new classification grading and monitoring systems for MG research studies. Discuss the use of thymectomy for the treatment of MG based on the 2016 published study, newly FDA-approved eculizumab, and other ongoing clinical research such as rituximab and gammaglobulins, intravenously and subcutaneously.

IF REGISTERING ONLINE YOU MUST LOGIN OR CREATE AN ACCOUNT IN CLOUD CME^TM PRIOR TO REGISTERING.

Payment is required at the time of registration. Please register in advance. Fees include course materials, breakfast, lunch, refreshments, and continuing education credit.

Physician _____________________________ $100

Non-Physician Healthcare Professional ______ $50

Residents _____________________________ $25

Pay online or make check payable to: University of Kansas Medical Center  

There will be no refunds for this course.

Complete this form and mail with payment to:

University of Kansas Medical Center

Continuing Education & Professional Development - MS 7010

4330 Shawnee Mission Parkway, Suite 2260

Fairway, KS 66205

ATTN: Kristi Day 

For questions about the course please contact Kristi Day:

Call 913-588-4483

Fax 913-588-4486

Email: kday2@kumc.edu

The University of Kansas Medical Center Office of Continuing Education and Professional Development is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

All participants are required to sign attendance rosters at the beginning of the program. A certificate of completion will be provided to all activity participants based on documentation of actual attendance time, and payment in full. If you are not paid in full your certificate will be mailed to you upon receipt of payment.

Physicians: Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The KU Medical Center Office of Continuing Medical Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits^TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The course will be held at the Detroit Marriott at the Renaissance Center, located in the heart of downtown and centrally located on the Riverwalk and many other Detroit attractions.

Detroit Marriott at Renaissance Center

400 Renaissance Drive, Detroit, MI

A block of rooms is available until July 28 at a rate of $170 per night (plus taxes). Call (877) 901-6632 for reservation and request the Neuromuscular Review Rate, or reserve  your room at:

https://book.passkey.com/go/NeuromuscularReviewCourse

PRIVACY POLICY

KU Medical Center Continuing Education does not share, sell, or rent its mailing lists. You have our assurance that any information you provide will be held in confidence by KU Medical Center Continuing Education.

We occasionally use mailing lists that we have leased. If you receive unwanted communication from KU Medical Center Continuing Education, it is because your name appears on a list we have acquired from another source. In this case, please accept our apologies.

NONDISCRIMINATION POLICY

The University of Kansas Medical Center prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University's programs and activities.  The following person has been designated to handle inquiries regarding the non-discrimination polices: Natalie Holick, Director, Equal Opportunity Office, NHolick@kumc.edu, Mail Stop 2014, 4330 Shawnee Mission Parkway, Fairway, KS 66205, 913-588-8011, 711TTY

PROGRAM ACCESSIBILITY

We accommodate persons with disabilities. Please call 913-588-4488 and a KU Medical Center Continuing Education representative will be happy to discuss your needs. To ensure accommodation, please register at least two weeks before the start of the course. See the nondiscrimination policy above. The University of Kansas Medical Center is an AA/EO Title IX institution.